巴西关于兽用抗寄生虫剂的专利申请
Cecilia Caroline S Alves1, Maria DA Glória A Bandeira2, Alexandra M S Soares1,3
1Universidade Federal do Maranhão, Centro de Ciências Exatas e Tecnologia, Departamento de Engenharia Química, Laboratório de Bioquímica Vegetal, Avenida dos Portugueses, 1966, Bacanga, 65080-805 São Luís, MA, Brazil.
Anais da Academia Brasileira de Ciencias
|December 10, 2025
概括
巴西公司在兽用抗寄生虫药物方面的创新领先,在1997-2022年期间申请了66项专利. 这一分析涵盖了动物健康研究的关键里程碑和法律影响.
科学领域:
- 兽医医学 兽医医学 兽医医学
- 知识产权法 知识产权法 知识产权法
- 动物卫生 动物健康
背景情况:
- 巴西是全球主要的牛肉生产国,拥有全球第三大物市场.
- 抗寄生虫药物对巴西的牲畜和伴侣动物都至关重要.
- 兽医抗寄生素药的创新对于动物健康和经济至关重要.
研究的目的:
- 分析1997年至2022年巴西兽用抗寄生虫药物的专利申请.
- 确定这些专利的关键趋势,申请人和地理分布.
- 了解历史和法律因素对该领域专利发展的影响.
主要方法:
- 从国家工业产权研究所 (INPI) 数据库提取数据.
- 对抗寄生虫化合物的66项专利的识别和编目.
- 专利根据地位,申请人类型和原产地进行分类.
主要成果:
- 公司是主要的专利持有者,主导着创新格局.
- 圣保罗和戈亚斯州的国内专利申请人数最多.
- 美国是巴西领先的非居民申请人.
结论:
- 该研究提供了25年来巴西兽医抗寄生虫药物创新的全面概述.
- 调查结果强调了企业实体在推动进步中的重要作用.
- 这项研究为未来的研究和巴西兽医寄生虫学技术发展提供了基础.
相关概念视频
Antibiotic Selection
59.3K
Overview
59.3K
Preclinical Development: Overview
5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Bioequivalence studies: Biowaivers
206
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
206


